BSE
MARKET ANALYSIS NEWS CORPORATE INFORMATION CORPORATE ACTIONS OTHER MARKETS
Your Result on : Company News Details
Cipla Ltd Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
500087
ISIN Demat
INE059A01026
Book Value (Rs)
423.3622252
NSE Symbol
CIPLA
Divident Yield %
0.92
Market Cap
(Rs In Cr.)
113,979
P/E (TTM)
34.76
EPS (TTM)
40.59
Face Value
(Rs)
2
Back
USFDA inspects Cipla subsidiary's manufacturing unit in New York
18-Jul-26   Hrs IST

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).

The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.

Risk Factor   |   Terms & Conditions   |   Privacy Policy   |   Disclaimer   |  Sitemap 
Important Links:   SEBI   |   NSE   |   BSE   |   MCX   |   NCDEX   |   NSDL   |   CDSL  |   FMC
SMS FINANCIAL SERVICES P. LTD -NSE SEBI No. AP1413004363 | BSE SEBI No. AP01091801121968
Ganesh S Shanbhag – AMFI Registered Mutual Fund Distributor. Registration Number – ARN-0988 – Valid Till 01/JUL/ 2027, Date of initial registration: 02/DEC/2004
2017-18 © SMS Financial Services. All rights reserved. Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)